Mathematical models of the epidemiology and control of drug-resistant TB

References

• WHO. Global tuberculosis control – surveillance, planning, financing. Geneva, Switzerland. WHO/HTM/TB/2008.393 (2008).
   Google Scholar
• World Health Organization. Anti-tuberculosis drug resistance in the world report no. 4. Geneva, Switzerland. WHO/HTM/TB/2008.394 (2008).
   Google Scholar
• Gandhi NR, Moll A, Sturm AW et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet368(9547), 1575–1580 (2006).
   PubMed Web of Science ®Google Scholar
• Gillespie S. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob. Agents Chemother.46(2), 267–274 (2002).
   PubMed Web of Science ®Google Scholar
• David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl. Microbiol.20(5), 810–814 (1970).
   PubMedGoogle Scholar
• Shah NS, Wright A, Bai G-H et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg. Infect. Dis.13(3), 380–387 (2007).
   PubMed Web of Science ®Google Scholar
• Vynnycky E, Fine PE. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol. Infect.119(2), 183–201 (1997).
   PubMed Web of Science ®Google Scholar
• Blower SM, McLean AR, Porco TC et al. The intrinsic transmission dynamics of tuberculosis epidemics. Nat. Med.1(8), 815–821 (1995).
   PubMed Web of Science ®Google Scholar
• Blower SM, Small PM, Hopewell PC. Control strategies for tuberculosis epidemics: new models for old problems. Science273(5274), 497–500 (1996).
   PubMed Web of Science ®Google Scholar
• Dye C, Garnett GP, Sleeman K, Williams BG. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet352(9144), 1886–1891 (1998).
   PubMed Web of Science ®Google Scholar
• Murray CJ, Salomon JA. Modeling the impact of global tuberculosis control strategies. Proc. Natl Acad. Sci. USA95(23), 13881–13886 (1998).
   PubMed Web of Science ®Google Scholar
• Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann. Intern. Med.149(2), 123–134 (2008).
   PubMed Web of Science ®Google Scholar
• Espinal MA, Kim SJ, Suarez PG et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA283(19), 2537–2545 (2000).
   PubMed Web of Science ®Google Scholar
• Lipsitch M, Levin BR. Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. Int. J. Tuberc. Lung Dis.2(3), 187–199 (1998).
   PubMed Web of Science ®Google Scholar
• Dye C, Espinal MA. Will tuberculosis become resistant to all antibiotics? Proc. Biol. Sci.268(1462), 45–52 (2001).
   PubMed Web of Science ®Google Scholar
• Danilchanka O, Mailaender C, Niederweis M. Identification of a novel multidrug efflux pump of Mycobacterium tuberculosis. Antimicrob. Agents Chemother.52(7), 2503–2511 (2008).
   PubMed Web of Science ®Google Scholar
• Boshoff HIM, Reed MB, Barry CE, Mizrahi V. DNAE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis. Cell113(2), 183–193 (2003).
   PubMed Web of Science ®Google Scholar
• Glynn JR, Whiteley J, Bifani PJ, Kremer K, van Soolingen D. Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review. Emerg. Infect. Dis.8(8), 843–849 (2002).
   PubMed Web of Science ®Google Scholar
• Cox HS, Kubica T, Doshetov D, Kebede Y, Rüsch-Gerdess S, Niemann S. The Beijing genotype and drug resistant tuberculosis in the Aral Sea region of Central Asia. Respir. Res.6, 134 (2005).
   PubMedGoogle Scholar
• Sun YJ, Lee ASG, Wong SY et al. Genotype and phenotype relationships and transmission analysis of drug-resistant tuberculosis in Singapore. Int. J. Tuberc. Lung Dis.11(4), 436–442 (2007).
   PubMedGoogle Scholar
• Almeida D, Rodrigues C, Ashavaid TF, Lalvani A, Udwadia ZF, Mehta A. High incidence of the Beijing genotype among multidrug-resistant isolates of Mycobacterium tuberculosis in a tertiary care center in Mumbai, India. Clin. Infect. Dis.40(6), 881–886 (2005).
   PubMedGoogle Scholar
• Alavez-Ramírez J, Castellanos JR, Esteva L et al. Within-host population dynamics of antibiotic-resistant M. tuberculosis. Math. Med. Biol.24(1), 35–56 (2007).
   PubMedGoogle Scholar
• Kirschner D. Dynamics of co-infection with M. tuberculosis and HIV-1. Theor. Popul. Biol.55(1), 94–109 (1999).
   PubMed Web of Science ®Google Scholar
• Demissie M, Lemma E, Gebeyehu M, Lindtjorn B. Sensitivity to anti-tuberculosis drugs in HIV-positive and -negative patients in Addis Ababa. Scand. J. Infect. Dis.33(12), 914–919 (2001).
   PubMedGoogle Scholar
• Espinal MA, Laserson K, Camacho M et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int. J. Tuberc. Lung Dis.5(10), 887–893 (2001).
   PubMed Web of Science ®Google Scholar
• Dye C, Williams BG, Espinal MA, Raviglione MC. Erasing the world’s slow stain: strategies to beat multidrug-resistant tuberculosis. Science295(5562), 2042–2046 (2002).
   PubMed Web of Science ®Google Scholar
• Peloquin CA, Nitta AT, Burman WJ et al. Low antituberculosis drug concentrations in patients with AIDS. Ann. Pharmacother.30(9), 919–925 (1996).
   PubMed Web of Science ®Google Scholar
• Tappero JW, Bradford WZ, Agerton TB et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin. Infect. Dis.41(4), 461–469 (2005).
   PubMed Web of Science ®Google Scholar
• Weiner M, Benator D, Burman W et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin. Infect. Dis.40(10), 1481–1491 (2005).
   PubMed Web of Science ®Google Scholar
• Blower SM, Gerberding JL. Understanding, predicting and controlling the emergence of drug-resistant tuberculosis: a theoretical framework. J. Mol. Med.76(9), 624–636 (1998).
   PubMedGoogle Scholar
• Dye C, Williams BG. Criteria for the control of drug-resistant tuberculosis. Proc. Natl Acad. Sci. USA297(14), 8180–8185 (2000).
   Google Scholar
• Castillo-Chavez C, Feng Z. To treat or not to treat: the case of tuberculosis. J. Math. Biol.35(6), 629–656 (1997).
   PubMed Web of Science ®Google Scholar
• Middlebrook G, Cohn ML. Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. Science118(3063), 297–299 (1953).
   PubMed Web of Science ®Google Scholar
• Davies AP, Billington OJ, Bannister BA, Weir WR, McHugh TD, Gillespie SH. Comparison of fitness of two isolates of Mycobacterium tuberculosis, one of which had developed multi-drug resistance during the course of treatment. J. Infect.41(2), 184–187 (2000).
   PubMed Web of Science ®Google Scholar
• Cohen T, Murray M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat. Med.10(10), 1117–1121 (2004).
   PubMed Web of Science ®Google Scholar
• Blower S, Chou T. Modeling the emergence of the ‘hot zones’: tuberculosis and the amplification dynamics of drug resistance. Nat. Med.10(10), 1111–1116 (2004).
   PubMed Web of Science ®Google Scholar
• van Soolingen D, de Haas PE, van Doorn HR, Kuijper E, Rinder H, Borgdorff MW. Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J. Infect. Dis.182(6), 1788–1790 (2000).
   PubMed Web of Science ®Google Scholar
• Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJM. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science312(5782), 1944–1946 (2006).
   PubMed Web of Science ®Google Scholar
• Gagneux S, Burgos MV, DeRiemer K et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog.2(6), E61 (2006).
   PubMed Web of Science ®Google Scholar
• Pym AS, Saint-Joanis B, Cole ST. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect. Immun.70(9), 4955–4960 (2002).
   PubMed Web of Science ®Google Scholar
• Cohen T, Sommers B, Murray M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect. Dis.3(1), 13–21 (2003).
   PubMed Web of Science ®Google Scholar
• Andersson DI, Levin BR. The biological cost of antibiotic resistance. Curr. Opin. Microbiol.2(5), 489–493 (1999).
   PubMed Web of Science ®Google Scholar
• DeRiemer K, García-García L, Bobadilla-del-Valle M et al. Does DOTS work in populations with drug-resistant tuberculosis? Lancet365(9466), 1239–1245 (2005).
   PubMed Web of Science ®Google Scholar
• Huong NT, Lan NTN, Cobelens FGJ et al. Antituberculosis drug resistance in the south of Vietnam: prevalence and trends. J. Infect. Dis.194(9), 1226–1232 (2006).
   PubMedGoogle Scholar
• Wallinga J, Teunis P. Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures. Am. J. Epidemiol.160(6), 509–516 (2004).
   PubMed Web of Science ®Google Scholar
• White LF, Pagano M. A likelihood-based method for real-time estimation of the serial interval and reproductive number of an epidemic. Stat. Med.27(16), 2999–3016 (2008).
   PubMedGoogle Scholar
• Vynnycky E, Fine PE. The long-term dynamics of tuberculosis and other diseases with long serial intervals: implications of and for changing reproduction numbers. Epidemiol. Infect.121(2), 309–324 (1998).
   PubMedGoogle Scholar
• Murray M, Alland D. Methodological problems in the molecular epidemiology of tuberculosis. Am. J. Epidemiol.155(6), 565–571 (2002).
   PubMedGoogle Scholar
• Murray M. Sampling bias in the molecular epidemiology of tuberculosis. Emerg. Infect. Dis.8(4), 363–369 (2002).
   PubMedGoogle Scholar
• Glynn JR, Vynnycky E, Fine PE. Influence of sampling on estimates of clustering and recent transmission of Mycobacterium tuberculosis derived from DNA fingerprinting techniques. Am. J. Epidemiol.149(4), 366–371 (1999).
   PubMedGoogle Scholar
• Laserson KF, Osorio L, Sheppard JD et al. Clinical and programmatic mismanagement rather than community outbreak as the cause of chronic, drug-resistant tuberculosis in Buenaventura, Colombia, 1998. Int. J. Tuberc. Lung Dis.4(7), 673–683 (2000).
   PubMed Web of Science ®Google Scholar
• Cohen T, Colijn C, Finklea B et al. Are survey-based estimates of the burden of drug resistant TB too low? Insight from a simulation study. PLoS ONE3(6), E2363 (2008).
   Google Scholar
• Wells CD, Cegielski JP, Nelson LJ et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J. Infect. Dis.196(Suppl. 1), S86–S107 (2007).
   PubMed Web of Science ®Google Scholar
• Corbett EL, Watt CJ, Walker N et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med.163(9), 1009–1021 (2003).
   PubMed Web of Science ®Google Scholar
• Ben Amor Y, Nemser B, Singh A, Sankin A, Schluger. Underreported threat of multidrug-resistant tuberculosis in Africa. Emerg. Infect. Dis.14(9), 1345–1352 (2008).
   PubMed Web of Science ®Google Scholar
• Currie CSM, Williams BG, Cheng RCH, Dye C. Tuberculosis epidemics driven by HIV: is prevention better than cure? AIDS17(17), 2501–2508 (2003).
   PubMedGoogle Scholar
• Dowdy DW, Chaisson RE, Moulton LH, Dorman SE. The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model. AIDS20(5), 751–762 (2006).
   PubMedGoogle Scholar
• Porco TC, Small PM, Blower SM. Amplification dynamics: predicting the effect of HIV on tuberculosis outbreaks. J. Acquir. Immune Defic. Syndr.28(5), 437–444 (2001).
   PubMedGoogle Scholar
• Sharomi O, Podder CN, Gumel AB, Song B. Mathematical analysis of the transmission dynamics of HIV/TB coinfection in the presence of treatment. Math. Biosci. Eng.5(1), 145–174 (2008).
   PubMed Web of Science ®Google Scholar
• Williams BG, Granich R, Chauhan LS, Dharmshaktu NS, Dye C. The impact of HIV/AIDS on the control of tuberculosis in India. Proc. Natl Acad. Sci. USA102(27), 9619–9624 (2005).
   PubMed Web of Science ®Google Scholar
• Bacaër N, Ouifki R, Pretorius C, Wood R, Williams B. Modeling the joint epidemics of TB and HIV in a South African township. J. Math. Biol.57(4), 557–593 (2008).
   PubMed Web of Science ®Google Scholar
• Narvskaya O, Otten T, Limeschenko E et al. Nosocomial outbreak of multidrug-resistant tuberculosis caused by a strain of Mycobacterium tuberculosis W-Beijing family in St. Petersburg, Russia. Eur. J. Clin. Microbiol. Infect. Dis.21(8), 596–602 (2002).
   PubMed Web of Science ®Google Scholar
• Moro ML, Gori A, Errante I et al. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. Italian Multidrug-Resistant Tuberculosis Outbreak Study Group. AIDS12(9), 1095–1102 (1998).
   PubMedGoogle Scholar
• Ritacco V, Lonardo MD, Reniero A et al. Nosocomial spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires. J. Infect. Dis.176(3), 637–642 (1997).
   PubMed Web of Science ®Google Scholar
• Kenyon TA, Ridzon R, Luskin-Hawk R et al. A nosocomial outbreak of multidrug-resistant tuberculosis. Ann. Intern. Med.127(1), 32–36 (1997).
   PubMedGoogle Scholar
• Edlin BR, Tokars JI, Grieco MH et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N. Engl. J. Med.326(23), 1514–1521 (1992).
   PubMed Web of Science ®Google Scholar
• Beck-Sagué C, Dooley SW, Hutton MD et al. Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients. JAMA268(10), 1280–1286 (1992).
   PubMed Web of Science ®Google Scholar
• Basu S, Andrews JR, Poolman EM et al. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet370(9597), 1500–1507 (2007).
   PubMed Web of Science ®Google Scholar
• Oeltmann JE, Varma JK, Ortega L et al. Multidrug-resistant tuberculosis outbreak among US-bound Hmong refugees, Thailand, 2005. Emerg. Infect. Dis.14(11), 1715–1721 (2008).
   PubMed Web of Science ®Google Scholar
• Mathema B, Kurepina NE, Bifani PJ, Kreiswirth BN. Molecular epidemiology of tuberculosis: current insights. Clin. Microbiol. Rev.19(4), 658–685 (2006).
   PubMed Web of Science ®Google Scholar
• Gagneux S, DeRiemer K, Van T et al. Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA103(8), 2869–2873 (2006).
   PubMed Web of Science ®Google Scholar
• Baker L, Brown T, Maiden MC, Drobniewski F. Silent nucleotide polymorphisms and a phylogeny for Mycobacterium tuberculosis. Emerg. Infect. Dis.10(9), 1568–1577 (2004).
   PubMed Web of Science ®Google Scholar
• Brosch R, Gordon SV, Marmiesse M et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc. Natl Acad. Sci. USA99(6), 3684–3689 (2002).
   PubMed Web of Science ®Google Scholar
• Filliol I, Motiwala AS, Cavatore M et al. Global phylogeny of Mycobacterium tuberculosis based on single nucleotide polymorphism (SNP) analysis: insights into tuberculosis evolution, phylogenetic accuracy of other DNA fingerprinting systems, and recommendations for a minimal standard SNP set. J. Bacteriol.188(2), 759–772 (2006).
   PubMed Web of Science ®Google Scholar
• Thwaites G, Caws M, Chau TTH et al. The relationship between Mycobacterium tuberculosis genotype and the clinical phenotype of pulmonary and meningeal tuberculosis. J. Clin. Microbiol.46(4), 1363–1368 (2008).
   PubMed Web of Science ®Google Scholar
• López B, Aguilar D, Orozco H et al. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin. Exp. Immunol.133(1), 30–37 (2003).
   PubMed Web of Science ®Google Scholar
• Valway SE, Sanchez MP, Shinnick TF et al. An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. N. Engl. J. Med.338(10), 633–639 (1998).
   PubMed Web of Science ®Google Scholar
• Hanekom M, van der Spuy GD, Streicher E et al. A recently evolved sublineage of the Mycobacterium tuberculosis Beijing strain family is associated with an increased ability to spread and cause disease. J. Clin. Microbiol.45(5), 1483–1490 (2007).
   PubMed Web of Science ®Google Scholar
• Gagneux S, Small PM. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect. Dis.7(5), 328–337 (2007).
   PubMed Web of Science ®Google Scholar
• Hanekom M, van der Spuy GD, van Pittius NCG et al. Evidence that the spread of Mycobacterium tuberculosis strains with the Beijing genotype is human population dependent. J. Clin. Microbiol.45(7), 2263–2266 (2007).
   PubMed Web of Science ®Google Scholar
• Mendelson M, Walters S, Smith I, Kaplan G. Strain-specific mycobacterial lipids and the stimulation of protective immunity to tuberculosis. Tuberculosis (Edinb.)85(5–6), 407–413 (2005).
   PubMed Web of Science ®Google Scholar
• Reed MB, Domenech P, Manca C et al. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature431(7004), 84–87 (2004).
   PubMed Web of Science ®Google Scholar
• Pheiffer C, Betts JC, Flynn HR, Lukey PT, van Helden P. Protein expression by a Beijing strain differs from that of another clinical isolate and Mycobacterium tuberculosis H37Rv. Microbiology151(Pt 4), 1139–1150 (2005).
   PubMed Web of Science ®Google Scholar
• Dormans J, Burger M, Aguilar D et al. Correlation of virulence, lung pathology, bacterial load and delayed type hypersensitivity responses after infection with different Mycobacterium tuberculosis genotypes in a BALB/c mouse model. Clin. Exp. Immunol.137(3), 460–468 (2004).
   PubMed Web of Science ®Google Scholar
• Rindi L, Peroni I, Lari N, Bonanni D, Tortoli E, Garzelli C. Variation of the expression of Mycobacterium tuberculosis ppe44 gene among clinical isolates. FEMS Immunol. Med. Microbiol.51(2), 381–387 (2007).
   PubMedGoogle Scholar
• Rodrigues P, Gomes MGM, Rebelo C. Drug resistance in tuberculosis – a reinfection model. Theor. Popul. Biol.71(2), 196–212 (2007).
   PubMed Web of Science ®Google Scholar
• Colijn C, Cohen T, Murray M. Latent coinfection and the maintenance of strain diversity. Bull. Math. Biol.71(1), 247–263 (2009).
   PubMedGoogle Scholar
• Feng Z, Iannelli M, Milner F. A two-strain TB model with age-structure. SIAM J. Appl. Math.62(5), 1634–1656 (2002).
   Web of Science ®Google Scholar
• Raviglione MC, Uplekar MW. WHO’s new Stop TB Strategy. Lancet367(9514), 952–955 (2006).
   PubMed Web of Science ®Google Scholar
• Han LL, Sloutsky A, Canales R et al. Acquisition of drug resistance in multidrug-resistant Mycobacterium tuberculosis during directly observed empiric retreatment with standardized regimens. Int. J. Tuberc. Lung Dis.9(7), 818–821 (2005).
   PubMedGoogle Scholar
• Sterling TR, Lehmann HP, Frieden TR. Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis. BMJ326(7389), 574 (2003).
   PubMedGoogle Scholar
• Pillay M, Sturm AW. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin. Infect. Dis.45(11), 1409–1414 (2007).
   PubMed Web of Science ®Google Scholar
• World Health Organization. The Stop TB Strategy: building on and enhancing DOTS to meet the TB-related millennium development goals. WHO, Geneva, Switzerland 2006 (WHO/HTM/TB/2006.368).
   Google Scholar
• Suárez PG, Floyd K, Portocarrero J et al. Feasibility and cost–effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet359(9322), 1980–1989 (2002).
   PubMed Web of Science ®Google Scholar
• Resch SC, Salomon JA, Murray M, Weinstein MC. Cost–effectiveness of treating multidrug-resistant tuberculosis. PLoS Med.3(7), E241 (2006).
   PubMed Web of Science ®Google Scholar
• Baltussen R, Floyd K, Dye C. Cost effectiveness analysis of strategies for tuberculosis control in developing countries. BMJ331(7529), 1364 (2005).
   PubMed Web of Science ®Google Scholar
• Dye C, Floyd K. Tuberculosis. Disease Control Priorities in Developing Countries (2nd Edition). Oxford, UK (2006).
   Google Scholar
• Basu S, Galvani AP. The transmission and control of XDR TB in South Africa: an operations research and mathematical modelling approach. Epidemiol. Infect.136(9), 1–14 (2008).
   PubMedGoogle Scholar
• Espinal MA, Dye C. Can DOTS control multidrug-resistant tuberculosis? Lancet365(9466), 1206–1209 (2005).
   PubMedGoogle Scholar
• Murray CJ, Salomon JA. Expanding the WHO tuberculosis control strategy: rethinking the role of active case-finding. Int. J. Tuberc. Lung Dis.2(9 Suppl. 1), S9–S15 (1998).
   Google Scholar
• Bayona J, Chavez-Pachas AM, Palacios E, Llaro K, Sapag R, Becerra MC. Contact investigations as a means of detection and timely treatment of persons with infectious multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis.7(12 Suppl. 3), S501–S509 (2003).
   Google Scholar
• Becerra MC, Pachao-Torreblanca IF, Bayona J et al. Expanding tuberculosis case detection by screening household contacts. Public Health Rep.120(3), 271–277 (2005).
   PubMed Web of Science ®Google Scholar
• Song B, Castillo-Chavez C, Aparicio JP. Tuberculosis models with fast and slow dynamics: the role of close and casual contacts. Math. Biosci.180, 187–205 (2002).
   PubMed Web of Science ®Google Scholar
• Aparicio JP, Capurro AF, Castillo-Chavez C. Transmission and dynamics of tuberculosis on generalized households. J. Theor. Biol.206(3), 327–341 (2000).
   PubMedGoogle Scholar
• Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg. Infect. Dis.12(5), 744–751 (2006).
   PubMed Web of Science ®Google Scholar
• Mtei L, Matee M, Herfort O et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin. Infect. Dis.40(10), 1500–1507 (2005).
   PubMed Web of Science ®Google Scholar
• Matee M, Mtei L, Lounasvaara T, Wieland-Alter W et al. Sputum microscopy for the diagnosis of HIV-associated pulmonary tuberculosis in Tanzania. BMC Public Health8, 68 (2008).
   PubMed Web of Science ®Google Scholar
• Cohen T, Lipsitch M, Walensky RP, Murray M. Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV–tuberculosis coinfected populations. Proc. Natl Acad. Sci. USA103(18), 7042–7047 (2006).
   PubMed Web of Science ®Google Scholar
• Atun RA, Lebcir R, Drobniewski F, Coker RJ. Impact of an effective multidrug-resistant tuberculosis control programme in the setting of an immature HIV epidemic: system dynamics simulation model. Int. J. STD AIDS16(8), 560–570 (2005).
   PubMed Web of Science ®Google Scholar
• Atun RA, Lebcir RM, McKee M, Habicht J, Coker RJ. Impact of joined-up HIV harm reduction and multidrug resistant tuberculosis control programmes in Estonia: system dynamics simulation model. Health Policy81(2–3), 207–217 (2007).
   PubMedGoogle Scholar
• Dowdy DW, Chaisson RE, Maartens G, Corbett EL, Dorman SE. Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc. Natl Acad. Sci. USA105(32), 11293–11298 (2008).
   PubMed Web of Science ®Google Scholar
• Barnard M, Albert H, Coetzee G, O’Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am. J. Respir. Crit. Care Med.177(7), 787–792 (2008).
   PubMed Web of Science ®Google Scholar
• Moore DAJ, Evans CAW, Gilman RH et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N. Engl. J. Med.355(15), 1539–1550 (2006).
   PubMed Web of Science ®Google Scholar
• Acuña-Villaorduña C, Vassall A, Henostroza G et al. Cost–effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries. Clin. Infect. Dis.47(4), 487–495 (2008).
   PubMed Web of Science ®Google Scholar
• Mitnick CD, Castro KG, Harrington M, Sacks LV, Burman W. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med.4(11), E292 (2007).
   PubMed Web of Science ®Google Scholar
• Cobelens FGJ, Heldal E, Kimerling ME et al. Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda. PLoS Med.5(7), E150 (2008).
   Google Scholar
• Spigelman M, Gillespie S. Tuberculosis drug development pipeline: progress and hope. Lancet367(9514), 945–947 (2006).
   PubMed Web of Science ®Google Scholar
• Salomon JA, Lloyd-Smith JO, Getz WM et al. Prospects for advancing tuberculosis control efforts through novel therapies. PLoS Med.3(8), E273 (2006).
   PubMedGoogle Scholar
• Godfrey-Faussett P, Sonnenberg P, Shearer SC et al. Tuberculosis control and molecular epidemiology in a South African gold-mining community. Lancet356(9235), 1066–1071 (2000).
   PubMed Web of Science ®Google Scholar
• Alland D, Kalkut GE, Moss AR et al. Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods. N. Engl. J. Med.330(24), 1710–1716 (1994).
   PubMed Web of Science ®Google Scholar
• Van Rie A, Warren R, Richardson M et al. Classification of drug-resistant tuberculosis in an epidemic area. Lancet356(9223), 22–25 (2000).
   PubMedGoogle Scholar
• Teixeira L, Perkins MD, Johnson JL et al. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis.5(4), 321–328 (2001).
   PubMed Web of Science ®Google Scholar
• Jia Z-W, Jia X-W, Liu Y-X et al. Spatial analysis of tuberculosis cases in migrants and permanent residents, Beijing, 2000–2006. Emerg. Infect. Dis.14(9), 1413–1419 (2008).
   PubMedGoogle Scholar